Skip to content
The Policy VaultThe Policy Vault

Lupron DepotMedical Mutual

Head and Neck Cancer – Salivary Gland Tumors

Initial criteria

  • Approve Lupron Depot 3.75 mg, 7.5 mg, 11.25 mg, or 22.5 mg for 1 year if:
  • A) Patient has recurrent, unresectable, or metastatic disease
  • B) Patient has androgen receptor (AR)-positive disease
  • C) Prescribed by or in consultation with an oncologist

Approval duration

1 year